Wyeth officials say their hormone replacement therapy Prempro is not the cause of one Ohio woman's breast cancer. But two jury decisions prove otherwise.

The first jury, in October, awarded Jennie Nelson and her husband $1.5 million in compensatory damages, validating Nelson's claim that her breast cancer -- resulting in a double mastectomy, chemotherapy, and radiation -- was caused by the Prempro she took for six years. When this verdict was thrown out due to a mistrial, a retrial began.

The retrial concluded yesterday -- with a Philadelphia jury awarding the Nelsons this time with $3 million.

"Both times this case has been heard on terms established by Wyeth and still the juries have clearly found that Prempro causes breast cancer," says Nelson's attorney Tobias Millrood, adding that Wyeth puts sales ahead of patient safety.

Wyeth respectfully disagrees and argues that it acted responsibly in the promotion of its hormone replacement products and in disclosing with doctors and patients all therapy-associated health risks.

Millions of women have used Wyeth's hormone replacement therapies to control the effects of menopause, and the company, sanctioned in January to pay $1 million to an Arkansas breast cancer survivor, now faces more than 5,000 lawsuits of this same nature.

Despite a large-scale study revealing drugs like Prempro increase the risk of breast cancer if used for five years or more, the drug still remains on the market. And Wyeth is so sure their drug is not at fault for causing Nelson's breast cancer that they plan to appeal yesterday's verdict.

A new study sheds new hopeful light on pancreatic cancer survival -- for patients 65 and older.

The study, conducted at Thomas Jefferson University and Thomas Jefferson University Hospital in Philadelphia, found patients in this age group who survive pancreatic cancer for at least five years have a better chance than patients not yet 65 at surviving another five years.

Researchers studied the records of 890 patients with pancreatic cancer who underwent the standard pancreaticoduodenectomy, or Whipple procedure. And lead researcher Charles Yeo reports that surgery can in fact extend and improve the quality of life for this population.

"Not too long ago, few lived for five years after diagnosis," he said. "Today, that not true. There's been a paradigm shift in the way we treat and think about this disease."

Additional details on this promising study can be found in the journal Surgery.

Michael Brecker, Grammy Award-winning jazz saxophonist who performed with the likes of Joni Mitchell and Herbie Hancock, died Saturday of cancer. He was 57.

Brecker, considered one of the most influential saxophonists of the past 25 years, died at a hospital in New York City as a result of myelodysplastic syndrome -- a form of cancer in which the bone marrow stops making healthy blood cells.

The Philadelphia native, who began his solo career in 1987 with a self-titled debut recording that turned into Jazz Album of the Year, was forced by his illness to stop playing music at times. So he channeled his creative efforts into raising awareness of a very important cause -- bone marrow donation.

Brecker is survived by his wife, Susan; his children, Jessica and Sam; a brother and a sister.

Sprycel is an oral agent that has recently been approved by the FDA. It works by stopping the production of proteins involved in cancer growth.

The American Society of Hematology presented results that stated that treatment with Sprycel (dasatinib) provides better outcomes compared to giving higher doses of Gleevec (imatinib), in patients with chronic myeloid leukemia (CML), who have stopped responding to standard doses of Gleevec.

In the clinical trial the patients were either treated with Sprycel or increased doses of Gleevec to see who had the better response.

Study results indicated:

• Patients who had achieved a major anticancer response with the standard dose of Gleevec initially, achieved a 35 percent complete response to Sprycel, compared with only 7 percent of those treated with the increased doses of Gleevec.
• Patients who did not receive a major anticancer response with the standard dose of Gleevec initially, achieved a 44 percent major anticancer response to Sprycel, compared to only 7 percent of those treated with the increased doses of Gleevec.
• The main side effect of Sprycel was low levels of blood cells, which may be partly corrected with the use of Neulasta.

The research has concluded that Sprycel provides superior responses to increased-doses of Gleevec among patients with chronic-phase CML who have stopped responding to prior Gleevec therapy.

Nilotinib is an investigational drug that targets the same protein as Gleevec, but through a different mechanism. Nilotinib, according to results recently presented at the 2006 meeting of the American Society of Hematology, is effective and well tolerated in patients with chronic-phase myeloid leukemia (CML) who do not respond to or cannot tolerate Gleevec.

In the past the only curative treatment for CML was a stem cell transplant. Researchers are focused on finding curative therapies that do not involve so much of a mortality risk and are more easily tolerated. A study was conducted to further evaluate the treatment with nilotinib in patients with CML who have stopped responding to Gleevec. Results of the study indicate that nilotinib was effective.

With over 30 celebrities including actor Cheech Marin, NFL MVP John Elway, World Series of Poker Champion Mel Judah, Hall of Fame Philly Mike Schmidt, Cock Blocker Clothing creator Mark James is raising money for the Philadelphia Breast Cancer 3Day Breast Cancer Foundation fundraiser by holding an eBay auction of celebrity-autographed Cock Blocker Clothing items. The auction is live now and will run through October 1, 2006 8PM (PST).

Supporting breast cancer research is personal for James of Cock Blocker Clothing, whose mother survives her own diagnosis of breast cancer. He wants to help other women who are going through the same struggles as his mother in contributing to something that can make a positive difference.

In addition to the celebrity-autographed Cock Blocker Clothing online eBay auction, James will be participating in Philadelphia's Breast Cancer 3Day fundraiser, where participants will walk 60 miles in three days, with each participant raising at least $10,000 dollars for the Susan G. Komen Breast Cancer Foundation.

To help with the cause, you can bid on celebrity-autographed Cock Blocker Clothing during the eBay auction, or donate directly to the 3Day event. The Philadelphia Breast Cancer 3Day Walk will take place on October 4 through the 6th.

"Please remember, all of us have the power to change lives and contribute to society," states James. Visit to learn more about the Cock Blocker Clothing fight against breast cancer.

A review was done by an international panel of experts of literature concerning chronic myeloid leukemia (CML) for the recommendation of treatment options. The panel included ten members that reviewed 194 papers on CML written since 1998.

The article was recently published in the journal Blood. Gleevec (imatinib mesylate) has become a standard treatment for Philadelphia chromosome-positive CML. Specific guidelines for the use of Gleevec in the treatment of CML have recently been compiled.

• All newly diagnosed patients should be treated with 400 mg of Gleevec per day.
• Patients who do not respond to Gleevec should be treated with higher doses, an allogeneic stem cell transplantation, or experimental therapy. This experimental therapy could include agents designed to over come resistance to Gleevec.

Responses to treatment can be determined by several laboratory tests. Talk to your physician about specific details regarding responses to Gleevec.

Acute lymphoblastic leukemia (ALL) is uncommon in adults between 15 and 50 years of age but occurs more frequently in individuals over 50 years of age. The Philadelphia chromosome is a specific gene mutation that occurs in about 20 percent of all ALL cases. The Philadelphia chromosome occurs when specific genetic information is switched. Patients who are Philadelphia chromosome positive typically do not respond well to standard therapies.

Researchers want to find new strategies to improve outcomes for Philadelphia chromosome positive ALL patients. Gleevec has shown some anticancer responses in these patients who no longer responded to standard treatments.

According to a study was done and published in the journal Leukemia, the survival at one year was 66 percent for those patients who received chemotherapy and Gleevec. Among comparison subjects the survival at one year was 43 percent.

What also sounded very promising was that the probability of surviving for one year without a relapse was 58 percent for those in the study and only 11 percent among comparison patients.

Living Beyond Breast Cancer (LBBC) is hosting a free networking meeting to focus on anxieties and emotions that women experience during and after breast cancer.

Moving On: Managing Anxiety and the Fear of Recurrence will be held on Thursday, September 28th, from 6:00 p.m. to 8:30 p.m. at the Philadelphia Marriott West in West Conshohocken, PA.

Some topics will include the common anxieties and emotions women experience after completing treatment, the impact of breast cancer diagnoses on relationships and outlook on life and strategies and tactics for dealing with anxiety and fear of recurrence.

The meeting will offer an opportunity to enjoy a light dinner and refreshments with women who share the same experiences.

Thanks to Patti Anastasi for the tip.

During my chemotherapy for breast cancer, I received the drug Adriamycin. Adriamycin is toxic and harsh and so powerful that when it makes contact with the skin it can cause a severe burn. How this drug cycled through my body without singeing my veins, I am not sure. Somehow, I survived it and can think back on this drug that is often called The Red Dragon.  It is wicked and fierce and unkind -- yet lifesaving as well.

The word dragon conjures up various images for me. I can clearly visualize the red liquid that dripped into my body many months ago with the purpose of attacking cancer cells. I also picture toy action figures that often cover my living room floor -- my five-year-old has a current love for dragons, and we have all shapes and sizes at our house. And lately, when I think of dragons, I see women in boats -- powerful women practicing the ancient sport of dragon boating.

I know women who participate in this sport through Team Survivor -- a group that provides free opportunities for physical fitness for women with cancer. And I just learned about Hope Afloat, Philadelphia and Pennsylvania's first breast cancer survivor dragon boat racing team.  With a mission of challenging their limits and not limiting their challenges, these women strive to awaken the dragon within through hope, support, and adventure.  This floating support group has been in existence since 2001 and welcomes all women with a history of breast cancer. Weekly practice, monthly meetings, and racing keeps these women in good shape and in good spirits. Go team!